You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

 

Online download statistics by month:

Online download statistics by month: May 2021 to August 2025

AbstractFullPdf
May 2021721721137
Jun 202128928949
Jul 202121821863
Aug 202114314327
Sep 202115215245
Oct 202115215236
Nov 202112112034
Dec 202110110113
Jan 20229810434
Feb 2022929732
Mar 2022767867
Apr 2022747635
May 2022676739
Jun 20229810836
Jul 202210010023
Aug 2022889122
Sep 2022919649
Oct 202210811448
Nov 2022707034
Dec 2022747427
Jan 2023677033
Feb 2023909030
Mar 202310911132
Apr 2023555524
May 2023818120
Jun 2023747420
Jul 2023828233
Aug 2023797922
Sep 2023717315
Oct 2023808031
Nov 2023797926
Dec 2023757528
Jan 2024767941
Feb 2024595937
Mar 2024999961
Apr 2024838331
May 2024737332
Jun 2024828236
Jul 2024747624
Aug 2024595825
Sep 2024626334
Oct 2024636433
Nov 2024707130
Dec 202410410844
Jan 2025727235
Feb 202512012088
Mar 2025878742
Apr 2025888847
May 2025737338
Jun 2025454526
Jul 2025110
Aug 2025110
Total526653221868